NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




GU Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Prostate

ECOG-ACRIN EA8153 - "Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial"

CANCER TYPE: Prostate
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03419234
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Prostate adenoca, progressive, soft tissue and/or bone mets, previous docetaxel, androgen deprivation and abiraterone and prednisone +/- cabazitaxel.






NRG-GU002 - "PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL"

CANCER TYPE: Prostate
RESEARCH BASE: NRG
NCT NUMBER: NCT03070886
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Post-prostatectomy, baseline Gleason ≥ 7, any pT, pN0 or pNX, no distant mets, adj. RT and androgen deprivation, with or without adj. docetaxel.






NRG-GU003 - "A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL POST-PROSTATECTOMY RADIATION THERAPY (COPORT)"

CANCER TYPE: Prostate
RESEARCH BASE: NRG
NCT NUMBER: NCT03274687
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Post radical prostatectomy, pT2 or pT3, pN0 or pNX, no bone mets, hypofractionated vs.conventional RT effects on GI and GU symptoms.






RTOG 0924 - "ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL"

CANCER TYPE: Prostate
RESEARCH BASE: NRG
NCT NUMBER: NCT01368588
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Prostate adenoca, moderate to high risk for recurrence, clinically negative lymph nodes, no bone mets, neoadj. androgen deprivation therapy and high dose RT w/wo whole pelvic RT.






Renal

ECOG-ACRIN EA8143 - "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)"

CANCER TYPE: Renal
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03055013
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Stage I,II or III RCC with planned nephrectomy, nivolumab + nephrectomy vs. nephrectomy + observation.  DCP-001 Eligible






SWOG S1500 - "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

CANCER TYPE: Renal
RESEARCH BASE: SWOG
NCT NUMBER: NCT02761057
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Stage IV, type I or II papillary renal carcinoma, cabozantinib vs. crizotinib vs. savolitinib vs. sunitinib









  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA